Tenaya Therapeutics, INC. (TNYA) — SEC Filings

Overview

Tenaya Therapeutics, INC. (TNYA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 16, 2026: Tenaya Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The report details the company's financial and operational status for the fiscal year 2025. Tenaya Therapeutics, Inc. is a biotechnology company focused on developi

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 1 bearish, 31 neutral, 2 mixed. The dominant filing sentiment for Tenaya Therapeutics, INC. is neutral.

Filing Type Overview

Tenaya Therapeutics, INC. (TNYA) has filed 1 ARS, 1 DEFA14A, 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Recent Filings (34)

• Tenaya Therapeutics Files 2025 Annual Report — ARS · Apr 16, 2026 Risk: low
  Tenaya Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 16, 2026, for the period ending December 31, 2025. The report details the c
• Tenaya Therapeutics Files Definitive Proxy Materials — DEFA14A · Apr 16, 2026 Risk: low
  Tenaya Therapeutics, Inc. filed a DEFA14A on April 16, 2026, which includes additional definitive proxy soliciting materials. The filing details information rel
• 8-K Filing — 8-K · Dec 12, 2025
• Tenaya Therapeutics Files 8-K Report — 8-K · Dec 11, 2025 Risk: low
  On December 11, 2025, Tenaya Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Stateme
• Tenaya Narrows Losses, Boosts Cash Amid R&D Streamlining — 10-Q · Nov 10, 2025 Risk: medium
  Tenaya Therapeutics, Inc. reported a net loss of $20.275 million for the three months ended September 30, 2025, a 20.8% improvement from the $25.634 million net
• 8-K Filing — 8-K · Nov 7, 2025
• Tenaya Narrows Q2 Loss, Boosts Cash with $100M Offering — 10-Q · Aug 6, 2025 Risk: high
  Tenaya Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company experience
• Tenaya Therapeutics Files 8-K on Shareholder Votes — 8-K · May 30, 2025 Risk: low
  Tenaya Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on matters submitted to a vote of security holders as of May 28, 2025. The filing details the
• Tenaya Therapeutics Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: medium
  Tenaya Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various agreements and events, including an At-The-Market Sale
• Tenaya Therapeutics Faces Delisting Concerns — 8-K · Apr 18, 2025 Risk: high
  Tenaya Therapeutics, Inc. filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
• Tenaya Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 17, 2025 Risk: low
  Tenaya Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 17, 2025, for its annual meeting on May 28, 2025. The company, focused on biol
• Tenaya Therapeutics Reports Exit/Disposal Costs — 8-K · Mar 28, 2025 Risk: medium
  On March 27, 2025, Tenaya Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The filing does not specify the ex
• Tenaya Therapeutics Files 2024 10-K — 10-K · Mar 10, 2025 Risk: medium
  Tenaya Therapeutics, Inc. filed its 2024 10-K on March 10, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on biological produ
• Tenaya Therapeutics Files 8-K with Material Agreement — 8-K · Mar 4, 2025 Risk: medium
  On March 3, 2025, Tenaya Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other ev
• Tenaya Therapeutics Announces Board and Executive Compensation Changes — 8-K · Feb 7, 2025 Risk: low
  On February 6, 2025, Tenaya Therapeutics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Chen was app
• Tenaya Therapeutics Appoints New CMO, Dr. Cook — 8-K · Jan 28, 2025 Risk: medium
  Tenaya Therapeutics, Inc. announced on January 24, 2025, the departure of its Chief Medical Officer, Dr. Faraz Ali. The company also announced the appointment o
• Tenaya Therapeutics Announces Board and Executive Changes — 8-K · Dec 17, 2024 Risk: medium
  Tenaya Therapeutics, Inc. announced on December 16, 2024, changes related to its board of directors and executive compensation. Specifically, the company report
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Tenaya Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Tenaya Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the three months e
• Tenaya Therapeutics Appoints New CMO, Director — 8-K · Sep 16, 2024 Risk: medium
  Tenaya Therapeutics, Inc. announced on September 12, 2024, the appointment of Dr. Faraz Ali as Chief Medical Officer and the election of Ms. Jennifer L. D. Fox
• Tenaya Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Tenaya Therapeutics, Inc. filed its Q2 2024 10-Q report on August 8, 2024, detailing its financial position as of June 30, 2024. The company, focused on biologi
• Tenaya Therapeutics Announces Board and Executive Changes — 8-K · Jul 25, 2024 Risk: low
  Tenaya Therapeutics, Inc. announced on July 19, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported t
• Tenaya Therapeutics Appoints New Director, Adjusts Executive Pay — 8-K · Jun 27, 2024 Risk: low
  Tenaya Therapeutics, Inc. announced on June 25, 2024, changes to its board of directors and executive compensation. Specifically, the company elected Dr. Jeffre
• Tenaya Therapeutics Holds 2024 Annual Meeting — 8-K · May 31, 2024 Risk: low
  On May 30, 2024, Tenaya Therapeutics, Inc. filed an 8-K report to announce the results of its 2024 Annual Meeting of Stockholders, which took place on May 29, 2
• Tenaya Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
  Tenaya Therapeutics, Inc. (TNYA) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Tenaya Therapeutics, Inc. filed a 10-Q report for the period endi
• Tenaya Therapeutics, Inc. Announces Annual Meeting of Stockholders — DEF 14A · Apr 17, 2024 Risk:
  Tenaya Therapeutics, Inc. (TNYA) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. Tenaya Therapeutics, Inc. will hold its annual meeting of sto
• Tenaya Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 18, 2024 Risk: medium
  Tenaya Therapeutics, Inc. (TNYA) filed a Annual Report (10-K) with the SEC on March 18, 2024. Tenaya Therapeutics, Inc. filed its 2023 Form 10-K on March 18, 20
• Column Group III Amends Tenaya Therapeutics Stake — SC 13D/A · Feb 14, 2024 Risk: low
  COLUMN GROUP III, LP filed an Amendment No. 2 to its Schedule 13D on February 14, 2024, regarding its beneficial ownership in Tenaya Therapeutics, Inc. This fil
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Tenaya Therapeutics Enters Material Definitive Agreement — 8-K · Feb 8, 2024 Risk: medium
  Tenaya Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" on February 7, 2024. This filing indicates
• BlackRock Discloses Passive Stake in Tenaya Therapeutics (TNYA) — SC 13G · Jan 31, 2024
  BlackRock Inc., a major investment firm, filed an SC 13G on January 31, 2024, disclosing its ownership in Tenaya Therapeutics, Inc. (TNYA) as of December 31, 20

Frequently Asked Questions